Email: cspc@cspc.cn
News
August 05, 2025
Share:
Previous: VOLUNTARY ANNOUNCEMENT - DUPILUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Next: VOLUNTARY ANNOUNCEMENT - ENTERING INTO EXCLUSIVE LICENSE AGREEMENT FOR SYH2086 WITH MADRIGAL
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us